title: Loss of Perineuronal Net in ME7 Prion Disease.
abstract: Microglial activation and behavioral abnormalities occur before neuronal loss in experimental murine prion disease; the behavioral changes coincide with a reduction in synaptic plasticity. Because synaptic plasticity depends on an intact perineuronal net (PN), a specialized extracellular matrix that surrounds parvalbumin (PV)-positive GABAergic (gamma-aminobutyric acid [GABA]) inhibitory interneurons, we investigated the temporal relationships between microglial activation and loss of PN and PV-positive neurons in ME7 murine prion disease. Anesthetized C57Bl/6J mice received bilateral intracerebral microinjections of ME7-infected or normal brain homogenate into the dorsal hippocampus. Microglial activation, PrP accumulation, the number of PV-positive interneurons, and Wisteria floribunda agglutinin-positive neurons (i.e. those with an intact PN) were assessed in the ventral CA1 and subiculum at 4, 8, 12, 16, and 20 weeks postinjection. Hippocampal areas and total neuron numbers in the ventral CA1 and subiculum were also determined. Loss of PN coincided with early microglial activation and with a reduction in synaptic plasticity. No significant loss of PV-positive interneurons was observed. Our findings suggest that the substrate of the earliest synaptic and behavioral abnormalities in murine prion disease may be inflammatory microglia-mediated degradation of the PN.
authors.affiliation: MRC Centre for Synaptic Plasticity, University of Bristol, Bristol, United Kingdom.
authors.forename: Sarah L
authors.initials: SL
authors.lastname: Franklin
authors.forename: Seth
authors.initials: S
authors.lastname: Love
authors.forename: J Richard T
authors.initials: JR
authors.lastname: Greene
authors.forename: Samar
authors.initials: S
authors.lastname: Betmouni
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D018450:Disease Progression; D004660:Encephalitis / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D005109:Extracellular Matrix / Q000378:metabolism / Q000473:pathology*; D005260:Female; D005911:Gliosis / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D006624:Hippocampus / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D007395:Interneurons / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D017628:Microglia / Q000378:metabolism / Q000473:pathology*; D009410:Nerve Degeneration / Q000276:immunology / Q000473:pathology; D009434:Neural Pathways / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D009473:Neuronal Plasticity; D010320:Parvalbumins / Q000378:metabolism; D037121:Plant Lectins; D018620:PrPSc Proteins / Q000378:metabolism; D017096:Prion Diseases / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D034781:Receptors, N-Acetylglucosamine; D013194:Staining and Labeling; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D010320:Parvalbumins; D037121:Plant Lectins; D018620:PrPSc Proteins; D034781:Receptors, N-Acetylglucosamine; C040129:wisteria lectin; D005680:gamma-Aminobutyric Acid